{"product_id":"admedsol-swot-analysis","title":"Advanced Medical Solutions Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAdvanced Medical Solutions Group shows resilient niche expertise in wound care and medical adhesives, supported by strong R\u0026amp;D and diversified distribution—but faces pricing pressure and regulatory risks that could constrain margins.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong R\u0026amp;D and Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced Medical Solutions Group reinvests about 8–9% of annual revenue into R\u0026amp;D (2024: £12.4m), sustaining a competitive edge in medtech. This funding built a strong portfolio of proprietary technologies, notably advanced tissue adhesives and internal fixation devices, and supported 6 product launches in 2023–24. Prioritizing innovation yields steady new products targeting unmet needs in surgical and wound care markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Surgical and Wound Care Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced Medical Solutions (AMS) splits revenue roughly 55\/45 between surgical and advanced wound care, giving a balanced stream that reduced segment volatility in 2025; surgical products (high-margin sutures, biosurgical devices) drove 28% gross margin while wound care (dressings, infection prevention) delivered stable recurring sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Compliance and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvanced Medical Solutions Group has navigated complex international regulation, completing MDR (EU) transition in 2021 and holding 40+ CE marks and 18 FDA approvals as of Q4 2025, enabling sales in top markets that account for ~65% of its £220m 2024 revenue; this regulatory depth creates a high barrier to entry for smaller rivals and underpins long-term market stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Position and Cash Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMS held net cash of approximately 45m GBP and generated operating cash flow of ~35m GBP in FY2025, with net debt at 0.1x EBITDA—supporting M\u0026amp;A and capex without heavy external funding.\u003c\/p\u003e\n\u003cp\u003eThat fiscal discipline underpins a progressive dividend (0.12p per share in 2025) and ongoing reinvestment into R\u0026amp;D and manufacturing capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet cash ~45m GBP\u003c\/li\u003e\n\u003cli\u003eOperating cash flow ~35m GBP (FY2025)\u003c\/li\u003e\n\u003cli\u003eNet debt ~0.1x EBITDA\u003c\/li\u003e\n\u003cli\u003eDividend 0.12p per share (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Strategic Partnerships and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpams has a global distribution network combining direct sales in key markets and third-party partners driving of revenues from recurring hospital contracts yielding yoy share growth europe apac.\u003e\n\u003cpthese partnerships deliver frontline clinician feedback used in product enhancements since and help ams secure preferred-supplier status at major hospitals keeping its devices standard care pathways.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e350+ distribution partners\u003c\/li\u003e\n\u003cli\u003e62% of 2024 revenue from recurring hospital contracts\u003c\/li\u003e\n\u003cli\u003e27 product updates since 2022\u003c\/li\u003e\n\u003cli\u003ePreferred supplier at 420 major hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pams\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: R\u0026amp;D-led surgical growth—£220m revenue, £45m net cash, 62% recurring hospital sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS reinvests ~8–9% revenue in R\u0026amp;D (2024: £12.4m), funding proprietary tissue adhesives and fixation devices; 6 launches in 2023–24. FY2025 revenue £220m with ~65% from top markets; gross margin surgical 28%. Net cash ~£45m, operating cash flow ~£35m, net debt 0.1x EBITDA; 350+ partners, 62% recurring hospital revenue, preferred at 420 hospitals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024)\u003c\/td\u003e\n\u003ctd\u003e£220m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e£12.4m (8–9%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash (FY2025)\u003c\/td\u003e\n\u003ctd\u003e£45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp cash flow (FY2025)\u003c\/td\u003e\n\u003ctd\u003e£35m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt \/ EBITDA\u003c\/td\u003e\n\u003ctd\u003e0.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution partners\u003c\/td\u003e\n\u003ctd\u003e350+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring hospital revenue\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreferred hospitals\u003c\/td\u003e\n\u003ctd\u003e420\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Advanced Medical Solutions Group, outlining its core strengths, operational weaknesses, growth opportunities, and external threats shaping strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Advanced Medical Solutions Group for rapid strategic alignment and clear stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Geographic Concentration in Western Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial 78% of Advanced Medical Solutions Group’s 2024 revenue came from the UK, EU and US, exposing the firm to regional GDP swings and policy shifts.\u003c\/p\u003e\n\u003cp\u003eThese are high-value markets, but reliance limits access to 6–8% CAGR growth seen in 2024–25 for APAC and LATAM healthcare markets, missing diversification upside.\u003c\/p\u003e\n\u003cp\u003eIf reimbursement cuts or regulatory changes reduce margins by 200–400 basis points in core regions, group EBITDA could fall by an estimated 12–18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Complexity from Recent Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group’s acquisitions, including Peters Surgical (closed 2024), raise integration complexity: merging cultures, IT stacks, and manufacturing caused a reported £8–12m of one-off integration costs in FY2024 and trimmed adjusted EBIT margin by ~120–180 bps in H2 2024.\u003c\/p\u003e\n\u003cp\u003eIf integrations lag, projected synergies of £20–30m over three years may not materialize, risking longer payback periods and lower ROIC than management modeled.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Key Product Franchises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite a broad portfolio, over 55% of AMS Group’s 2024 operating profit came from flagship lines LiquiBand and RESORBA, concentrating earnings in few products.\u003c\/p\u003e\n\u003cp\u003eThat concentration raises material risk: a recall or tech obsolescence in either brand could cut EBITDA by an estimated 30–40% given current margins.\u003c\/p\u003e\n\u003cp\u003eManagement reports new-product revenue at 12% of 2024 sales, so diversifying contribution remains a critical, ongoing challenge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Raw Material Cost Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe manufacturing of advanced wound care and surgical products relies on medical-grade polymers and specialty components whose prices rose ~8–12% in 2024, exposing AMS Group to input-cost shocks that can erode margins if price increases cannot be passed to buyers.\u003c\/p\u003e\n\u003cp\u003eRising energy costs and freight rates (global container rates up ~30% in 2023–24) further compress margins, while a complex global supply chain raises risks from delayed procurement and spot-purchase premiums.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a 10% raw-material cost increase could cut adjusted gross margin by ~2–4 percentage points for product lines with 20–40% gross margins; what this estimate hides is product mix and contract pricing rigidity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRaw-material inflation 8–12% (2024)\u003c\/li\u003e\n\u003cli\u003eContainer rates +30% (2023–24)\u003c\/li\u003e\n\u003cli\u003ePotential 2–4 ppt gross-margin hit from 10% input rise\u003c\/li\u003e\n\u003cli\u003eSupply-chain timing risk increases procurement costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller Scale Compared to Global Medtech Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile AMS leads in wound-care niches, it is much smaller than Johnson \u0026amp; Johnson (2024 revenue $77.1B) and Medtronic ($33.9B), which constrains AMS’s bargaining power with large hospital groups and group purchasing organizations.\u003c\/p\u003e\n\u003cp\u003eSmaller scale limits AMS’s ability to match rivals’ marketing spend—J\u0026amp;J R\u0026amp;D and marketing were ~$13B in 2024—so AMS must stay agile and focus on specialized innovation to protect share.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: AMS FY2024 revenue ~£250–300M vs giants’ tens of billions; that gap drives procurement and marketing disadvantages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue: AMS ~£250–300M (estimate)\u003c\/li\u003e\n\u003cli\u003eCompetitors: J\u0026amp;J $77.1B, Medtronic $33.9B (2024)\u003c\/li\u003e\n\u003cli\u003eJ\u0026amp;J R\u0026amp;D\/marketing ~ $13B (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: weaker negotiating leverage with GPOs\u003c\/li\u003e\n\u003cli\u003eMitigation: niche R\u0026amp;D, faster product cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk: 78% regional exposure \u0026amp; 55% profit from two products threaten EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh regional concentration: 78% revenue from UK\/EU\/US (2024) exposes AMS to policy\/GDP swings; limited APAC\/LATAM exposure misses 6–8% CAGR growth. Product and margin concentration: LiquiBand\/RESORBA = 55% operating profit; recall or obsolescence could cut EBITDA 30–40%. Integration and cost pressure: £8–12m one-off integration costs (FY2024), raw-materials +8–12% and container rates +30% tightened margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration (UK\/EU\/US)\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlagship profit share\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration costs\u003c\/td\u003e\n\u003ctd\u003e£8–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material inflation\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContainer rates change\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAdvanced Medical Solutions Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the complete, editable version becomes available after checkout. You’re viewing a live preview of the real file; buy now to access the full, detailed report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752316547449,"sku":"admedsol-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/admedsol-swot-analysis.png?v=1772239440","url":"https:\/\/matrixbcg.com\/products\/admedsol-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}